Sg3 Management, LLC Rigel Pharmaceuticals Inc Call Options Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $33,500 - $159,500	-50,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $111,000 - $172,500	50,000 New	50,000 $150,000
Q4 2021 Feb 15, 2022	SELL	$2.36 - $3.57 $236,000 - $357,000	-100,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $88,200 - $113,400	25,200 Added 33.69%	100,000 $363,000
Q2 2021 Aug 16, 2021	SELL	$3.09 - $4.54 $427,965 - $628,790	-138,500 Reduced 64.93%	74,800 $325,000
Q1 2021 May 17, 2021	BUY	$3.35 - $4.93 $542,030 - $797,674	161,800 Added 314.17%	213,300 $729,000
Q4 2020 Feb 16, 2021	BUY	$2.35 - $3.74 $32,900 - $52,360	14,000 Added 37.33%	51,500 $180,000
Q3 2020 Nov 13, 2020	BUY	$1.78 - $4.13 $66,750 - $154,875	37,500 New	37,500 $90,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $4.82B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.